FDA amends opioid action warning

Share this article:
The Food and Drug Administration will temporarily allow the continued production, marketing and distribution of one particular type of opioid, which is widely used to alleviate pain in terminally ill patients.

The action is in response to a March 30 warning that it issued to manufacturers to stop producing certain unapproved prescription opioids.  Concerns from palliative care patients and healthcare professionals prompted the FDA to amend the warning. They were concerned that the original order would cause a shortage of morphine sulfate oral solution.

The agency has determined that the 20 milligram dosage form of morphine sulfate oral solution is medically necessary and should remain on the market until an approved alternative becomes available.

Share this article:

More in News

Antipsychotics reduction goal raised to 30% by end of 2016, CMS and provider groups announce

Antipsychotics reduction goal raised to 30% by end ...

Long-term care providers are being asked to reduce the use of antipsychotic medications among residents by 25% by the end of 2015, and 30% by the end of 2016. Providers ...

CDC issues new guidelines on pneumococcal vaccine, says LTC flu vaccination rates remain low

CDC issues new guidelines on pneumococcal vaccine, says ...

Long-term care workers continued to have low rates of flu vaccination last season, despite there being 92% vaccination coverage overall among physicians and nurses, the Centers for Disease Control and ...

AL operators accused of withholding $2M in unpaid overtime, minimum wages ...

Four California assisted living operators are facing eight felony charges related to wage theft, tax and insurance violations, according to local reports.